As a result of the court ruling, this marks the end of the FDA enforcement discretion as follows: Small-scale compounders (i.e., 503A facilities), licensed by individual states and physician compounding, must stop producing compounded semaglutide immediately
DeBergeMLantzCDehnSSullivanDPvan der LaanAMNiessenHWMet al
Participants on tirzepatide were also more likely to achieve weight reductions of 10%, 15%, 20%, and 25% compared to those on semaglutide
Of those patients, 710 had type 2 diabetes, 194 of whom had been prescribed semaglutide, and 975 were overweight, 361 of whom had been prescribed semaglutide
Gherardini J, Wegner J, Chret J, Ghatak S, Lehmann J, Alam M, Ward C
One notable study is the SUSTAIN 6 trial, which involved over 3,000 participants with type 2 diabetes and established cardiovascular disease